Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19213875 | SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS | May 2025 | August 2025 | Allow | 3 | 1 | 0 | No | No |
| 19205807 | SUBSTITUTED 1',2'-DIHYDRO-3'H-SPIRO[CYCLOHEXANE-1,4'-PYRIMIDO[5',4':4,5]PYRROLO[2,1-c][1,2,4]TRIAZIN]-3'-ONES AS CYCLIN-DEPENDENT KINASE INHIBITORS | May 2025 | October 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 19072824 | (R)-N-(4-(CHLORODIFLUOROMETHOXY)PHENYL)-2-(DIFLUOROMETHYL)-1-(1-HYDROXYPROPAN-2-YL)-7-(PYRIMIDIN-5-YL)-1H-BENZO[D]IMIDAZOLE-5-CARBOXAMIDE, OR A PHARMACEUTICALLY ACCEPTABLE SALT OR TAUTOMER THEREOF, FOR TREATING CERTAIN LEUKEMIAS | March 2025 | September 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 19016827 | SUBSTITUTED QUINAZOLINES AS HDAC6 INHIBITORS | January 2025 | July 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 19015403 | SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS | January 2025 | July 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 18948031 | CRYSTALLINE FORMS OF 4-ETHOXY-N-(2-METHOXYETHYL)-N-METHYL-3-(5-METHYL-4-OXO-7-PROPYL-3,4-DIHYDROIMIDAZO[5,1-f][1,2,4]TRIAZIN-2-YL)BENZENESULFONAMIDE | November 2024 | February 2025 | Allow | 3 | 1 | 0 | Yes | No |
| 18927377 | 3-(ETHOXYDIFLUOROMETHYL)-6-(5-FLUORO-6-(2,2,2-TRIFLUOROETHOXY)PYRIDIN-3-YL)-[1,2,4]TRIAZOLO[4,3-a]PYRAZINE AS AN ION CHANNEL MODULATOR | October 2024 | November 2025 | Allow | 13 | 2 | 0 | Yes | No |
| 18723033 | SUBSTITUTED MORPHOLINES AS ATR KINASE INHIBITORS | August 2024 | June 2025 | Allow | 12 | 1 | 1 | Yes | No |
| 18721449 | SUBSTITUTED PIPERIDINES AND PIPERAZINES AND METHODS FOR THE TREATMENT OF CNS DISORDERS | June 2024 | April 2025 | Allow | 10 | 1 | 0 | Yes | No |
| 18741739 | PHARMACEUTICAL COMPOSITIONS COMPRISING 4-((6bR,10aS)-3-METHYL-2,3,6b,9,10,10a-HEXAHYDRO-1H-PYRIDO[3',4':4,5]PYRROLO[1,2,3-de]QUINOXALIN-8(7H)-YL)-1-(4-((6bR,10aS)-3-METHYL-2,3,6b,9,10,10a-HEXAHYDRO-1H-PYRIDO[3',4':4,5]PYRROLO[1,2,3-de]QUINOXALIN-8(7H)-YL)PHENYL)BUTAN-1-ONE FOR TREATING CONDITIONS OF THE CENTRAL NERVOUS SYSTEM AND CARDIAC DISORDERS | June 2024 | December 2024 | Allow | 7 | 1 | 0 | Yes | No |
| 18661225 | CRYSTALLINE FORM OF DEURUXOLITINIB PHOSPHATE | May 2024 | August 2024 | Allow | 3 | 0 | 0 | Yes | No |
| 18658960 | CRYSTAL FORM OF XEVINAPANT FOR TREATING LA SCCHN | May 2024 | July 2024 | Allow | 3 | 0 | 0 | Yes | No |
| 18653538 | SUBSTITUTED PYRIDINES AS PARP1 INHIBITORS | May 2024 | May 2025 | Allow | 12 | 0 | 1 | Yes | No |
| 18632213 | SUBSTITUTED [1,2,4]TRIAZOLO[4,3-C]PYRIMIDINES THAT INDUCE DEGRADATION OF EMBRYONIC ECTODERM DEVELOPMENT (EED) PROTEIN | April 2024 | July 2025 | Allow | 15 | 1 | 1 | Yes | No |
| 18630561 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | April 2024 | January 2026 | Abandon | 21 | 1 | 0 | No | No |
| 18629648 | SUBSTITUTED CYCLOPENTA[c]PYRROLES AS ABHD6 ANTAGONISTS | April 2024 | December 2025 | Allow | 20 | 2 | 0 | Yes | No |
| 18628280 | SUBSTITUTED PYRIMIDINES AND 1,3,5-TRIAZINES AS RHOJ INHIBITORS | April 2024 | August 2025 | Allow | 16 | 1 | 0 | Yes | No |
| 18627407 | SUBSTITUTED PYRIMIDO[4,5-b]INDOLES AS CK2 INHIBITORS | April 2024 | March 2025 | Allow | 11 | 1 | 1 | Yes | No |
| 18627412 | SUBSTITUTED PYRIMIDO[4,5-b]INDOLES AS CK2 INHIBITORS | April 2024 | October 2024 | Allow | 7 | 1 | 1 | Yes | No |
| 18624178 | PROCESS FOR PREPARING SUBSTITUTED IMIDAZO[4,5-c]PYRAZOLES | April 2024 | August 2024 | Allow | 4 | 1 | 0 | Yes | No |
| 18623738 | SUBSTITUTED PYRROLO[1,2-b]PYRIDAZINES AS BIFUNCTIONAL DEGRADERS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES | April 2024 | August 2025 | Allow | 17 | 1 | 0 | No | No |
| 18622428 | SUBSTITUTED PYRROLO[1,2-b]PYRIDAZINES AS ANTHELMINTICS | March 2024 | August 2025 | Allow | 17 | 1 | 0 | Yes | No |
| 18614458 | POLYMORPHIC FORMS OF (S)-N-(3-BROMO-2-FLUOROPHENYL)-7-((4-METHYLPIPERAZIN-1-YL)METHYL)-7,8-DIHYDRO-[1,4]DIOXINO[2,3-g]QUINAZOLIN-4-AMINE AS EGFR INHIBITORS | March 2024 | October 2025 | Allow | 19 | 2 | 1 | Yes | No |
| 18441757 | SUBSTITUTED IMIDAZO[1,2-A]QUINAZOLINES AS INHIBITORS OF PARG | February 2024 | August 2025 | Allow | 18 | 1 | 1 | No | No |
| 18437153 | CRYSTALLINE FORMS OF AN IRREVERSIBLE INHIBITOR OF MENIN-MLL INTERACTION | February 2024 | December 2025 | Abandon | 22 | 1 | 1 | No | No |
| 18434620 | PROCESS FOR MAKING (E)-7-(4-((5-((2-CHLOROBENZYLIDENE)AMINO)-2-THIOXO-1,3,4-THIADIAZOL-3(2H)-YL)METHYL)PIPERAZIN-1-YL)-1-CYCLOPROPYL-6-FLUORO-4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID | February 2024 | July 2024 | Allow | 6 | 1 | 0 | Yes | No |
| 18427226 | CRYSTALLINE FORMS OF N-[4-[4-(4-MORPHOLINYL)-7H-PYRROLO[2,3-d]PYRIMIDIN-6-YL]PHENYL]-4-[[3(R)-[(1-OXO-2-PROPEN-1-YL)AMINO]-1-PIPERIDINYL]METHYL]-2-PYRIDINECARBOXAMIDE | January 2024 | July 2024 | Allow | 6 | 0 | 0 | Yes | No |
| 18423972 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS | January 2024 | October 2025 | Abandon | 20 | 1 | 0 | No | No |
| 18420017 | SUBSTITUTED PYRIMIDINES AS VACCINE ADJUVANTS | January 2024 | May 2025 | Allow | 16 | 1 | 1 | No | No |
| 18414988 | SUBSTITUTED FATTY ACIDS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | January 2024 | July 2025 | Allow | 18 | 1 | 0 | No | No |
| 18414456 | COMPOSITIONS FOR TREATING AND/OR PREVENTING CELL OR TISSUE NECROSIS SPECIFICALLY TARGETING CATHEPSIN C AND/OR CELA1 AND/OR CELA3A AND/OR STRUCTURALLY RELATED ENZYMES THERETO | January 2024 | May 2025 | Abandon | 16 | 0 | 1 | No | No |
| 18413246 | SUBSTITUTED PYRIDO[4,3-e]PYRROLO[1,2-a]PYRAZINES AS CK2 INHIBITORS | January 2024 | July 2024 | Allow | 6 | 1 | 1 | Yes | No |
| 18409478 | SUBSTITUTED PIPERAZINES AS DOPAMINE D3/D2 RECEPTOR MODULATORS | January 2024 | July 2024 | Allow | 6 | 1 | 0 | No | No |
| 18401896 | SUBSTITUTED PYRROLO[1,2-a]QUINOXALIN-4(5H)-ONES AS CX3CR1 ANTAGONISTS | January 2024 | January 2026 | Allow | 25 | 2 | 0 | Yes | No |
| 18393274 | ANTI-LIFERATIVE AGENTS COMPRISING SUBSTITUTED BENZO[e]PYRIDO[1,2-a][1,4]DIAZEPINES | December 2023 | June 2025 | Allow | 18 | 1 | 0 | Yes | No |
| 18392679 | SUBSTITUTED PYRIMIDO[6’,1’:2,3]IMIDAZO[4,5-c][1,6]NAPHTHYRIDINES AS CK2 INHIBITORS | December 2023 | March 2024 | Allow | 3 | 1 | 0 | Yes | No |
| 18545059 | SUBSTITUTED PYRAZINO[1',2':1,5]PYRAZOLO[4,3-c][1,6]NAPHTHYRIDINES AS CK2 INHIBITORS | December 2023 | February 2025 | Allow | 14 | 1 | 1 | Yes | No |
| 18545952 | SUBSTITUTED AMINO ACIDS AS INTEGRIN INHIBITORS | December 2023 | May 2025 | Abandon | 17 | 0 | 1 | No | No |
| 18543923 | SUBSTITUTED DIPYRIDO[1,2-a:1',2'-d]PYRAZINES FOR TREATING VIRAL INFECTIONS | December 2023 | September 2025 | Allow | 21 | 1 | 0 | No | No |
| 18539527 | PROCESS FOR PREPARING METHYL 3-BROMO-2-(2,3,4,9-TETRAHYDRO-1H-PYRIDO[3,4-B]INDOL-1-YL)PROPANOATE | December 2023 | June 2024 | Allow | 6 | 0 | 1 | Yes | No |
| 18539773 | SOLID FORMS OF A HBV CORE PROTEIN ALLOSTERIC MODIFIER | December 2023 | August 2025 | Allow | 20 | 1 | 0 | Yes | No |
| 18536817 | SUBSTITUTED PYRROLO[3,4-c]PYRIDINES AS HPK1 ANTAGONISTS | December 2023 | June 2025 | Allow | 19 | 1 | 0 | Yes | No |
| 18529046 | PROCESSES FOR THE PREPARATION OF SUBSTITUTED 1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-b]INDOLES | December 2023 | June 2025 | Allow | 18 | 1 | 0 | Yes | No |
| 18515989 | SUBSTITUTED NUCLEOSIDES AND NUCLEOTIDES FOR TREATING VIRAL INFECTIONS | November 2023 | March 2025 | Allow | 16 | 1 | 1 | Yes | No |
| 18508503 | SUBSTITUTED 7,8-DIHYDROPYRIMIDO[4,5-d]PYRIMIDINES AS ANTI-TUBERCULAR AGENTS | November 2023 | March 2024 | Allow | 4 | 1 | 0 | Yes | No |
| 18502729 | SUBSTITUTED CYCLOALKANES FOR MANAGING NEPHROGENIC DIABETES INSIPIDUS | November 2023 | June 2025 | Allow | 19 | 1 | 0 | Yes | No |
| 18386964 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES FOR MODULATING CDK9 ACTIVITY | November 2023 | March 2026 | Allow | 28 | 2 | 1 | Yes | No |
| 18500155 | SUBSTITUTED INDAZOLES AS IRAK4 INHIBITORS | November 2023 | June 2025 | Allow | 20 | 2 | 0 | Yes | No |
| 18499669 | HER2 MUTATION INHIBITORS | November 2023 | September 2025 | Abandon | 22 | 1 | 1 | No | No |
| 18488925 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS CFTR MODULATORS | October 2023 | May 2025 | Abandon | 19 | 0 | 1 | No | No |
| 18488924 | SUBSTITUTED HETEROCYCLES AS ALDEHYDE DEHYDROGENASE INHIBITORS | October 2023 | March 2024 | Allow | 5 | 1 | 1 | Yes | No |
| 18487325 | PROCESS FOR PREPARING SUBSTITUTED IMIDAZO[4,5-c]PYRAZOLES | October 2023 | September 2024 | Allow | 11 | 0 | 0 | Yes | No |
| 18376754 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES AS INHIBITORS FOR MULTI-RESISTANT CANCERS | October 2023 | March 2025 | Allow | 17 | 1 | 1 | Yes | No |
| 18375628 | SUBSTITUTED DIAZASPIROALKANES AS ANDROGEN RECEPTOR MODULATORS | October 2023 | October 2025 | Abandon | 24 | 1 | 1 | No | No |
| 18375645 | INHIBITORS OF BRUTON'S TYROSINE KINASE | October 2023 | November 2025 | Abandon | 25 | 1 | 1 | No | No |
| 18472970 | SUBSTITUTED CYCLOPENTA[c]PYRROLES AS ABHD6 ANTAGONISTS | September 2023 | January 2024 | Allow | 4 | 0 | 1 | Yes | No |
| 18371126 | DIMETHYL 7-BROMO-1-(4-SUBSTITUTED BENZOYL)PYRROLO[1,2-A]QUINOLINE-2,3-DICARBOXYLATES AS ANTI-INFLAMMATORY AGENTS | September 2023 | January 2024 | Allow | 4 | 1 | 0 | Yes | No |
| 18471250 | SUBSTITUTED PYRIDINES AS PARP1 INHIBITORS | September 2023 | March 2024 | Allow | 5 | 1 | 0 | Yes | No |
| 18369528 | SUBSTITUTED PYRIMIDO[4,5-b]INDOLES AS CK2 INHIBITORS | September 2023 | March 2024 | Allow | 6 | 2 | 1 | Yes | No |
| 18368205 | SUBSTITUTED PYRROLO[2,3-d]PYRIMIDINES AS CK2 INHIBITORS | September 2023 | February 2024 | Allow | 5 | 1 | 1 | Yes | No |
| 18367093 | SUBSTITUTED PYRIDO[3',4':4,5]PYRROLO[3,2-c][1,6]NAPHTHYRIDINES AS CK2 INHIBITORS | September 2023 | February 2024 | Allow | 5 | 1 | 1 | Yes | No |
| 18242434 | 3-((1R,3s,5S)-3-((7-((5-METHYL-1H-PYRAZOL-3-YL)AMINO)-1,6-NAPHTHYRIDIN-5-YL)AMINO)-8-AZABICYCLO[3.2.1]OCTAN-8-YL)PROPANENITRILE AS A JAK KINASE INHIBITOR | September 2023 | March 2025 | Allow | 18 | 1 | 0 | No | No |
| 18240951 | PHARMACEUTICAL COMPOSITIONS COMPRISING 4-((6bR,10aS)-3-METHYL2,3,6b,9,10,10a-HEXAHYDRO-1H-PYRIDO[3',4':4,5]PYRROLO[1,2,3-de]QUINOXALIN8(7H)-YL)-1-(4-((6bR,10aS)-3-METHYL-2,3,6b,9,10,10a-HEXAHYDRO-1H-PYRIDO[3',4':4,5]PYRROLO[1,2,3-de]QUINOXALIN-8(7H)-YL)PHENYL)BUTAN-1-ONE FOR TREATING CONDITIONS OF THE CENTRAL NERVOUS SYSTEM AND CARDIAC DISORDERS | August 2023 | September 2024 | Allow | 12 | 1 | 0 | Yes | No |
| 18239940 | 3-SUBSTITUTED AMINO-2-ARYLPYRROLO[2,3-c]PYRIDINES AS CK2 INHIBITORS | August 2023 | November 2023 | Allow | 3 | 1 | 1 | Yes | No |
| 18457868 | SUBSTITUTED IMIDAZO[1,2-a]PYRAZINES AS LUCIFERASE SUBSTRATES | August 2023 | April 2025 | Allow | 19 | 1 | 0 | No | No |
| 18238949 | SUBSTITUTED IMIDAZO [1,2-b] PYRIDAZINES AND [1, 2, 4] TRIAZOLO [ 4,3-b] PYRIDAZINES AS CAMKII INHIBITORS | August 2023 | September 2025 | Allow | 25 | 2 | 1 | Yes | No |
| 18236021 | SUBSTITUTED PYRIDO[3',4':4,5]PYRROLO[3,2-b][1,6]NAPHTHYRIDINES AS CK2 INHIBITORS | August 2023 | January 2024 | Allow | 5 | 1 | 1 | Yes | No |
| 18235976 | NOVEL N-ACYL-[3-SUBSTITUTED]-[8-SUBSTITUTED]-5,6-DIHYDRO-[1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERS | August 2023 | July 2025 | Abandon | 23 | 1 | 0 | No | No |
| 18236156 | 3-(ETHOXYDIFLUOROMETHYL)-6-(5-FLUORO-6-(2,2,2-TRIFLUOROETHOXY)PYRIDIN-3-YL)-[1,2,4]TRIAZOLO[4,3-a]PYRAZINE AS AN ION CHANNEL MODULATOR | August 2023 | February 2025 | Allow | 18 | 1 | 0 | Yes | No |
| 18450253 | METHODS AND COMPOSITIONS FOR REDUCING BODY FAT AND ADIPOCYTES | August 2023 | January 2025 | Abandon | 17 | 0 | 1 | No | No |
| 18365695 | SUBSTITUTED [1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS ION CHANNEL MODULATORS | August 2023 | July 2024 | Allow | 11 | 0 | 0 | Yes | No |
| 18229399 | SUBSTITUTED PYRIDO[3',4':4,5]PYRROLO[2,3-c]QUINOLINES AS CK2 INHIBITORS | August 2023 | November 2023 | Allow | 3 | 1 | 1 | Yes | No |
| 18229579 | METHOD OF PREPARING INDOLINOBENZODIAZEPINE DERIVATIVES | August 2023 | June 2025 | Abandon | 22 | 1 | 0 | No | No |
| 18228911 | SUBSTITUTED 5,6,7,8-TETRAHYDROPYRIDO[2,3-D]PYRIMIDINE-2,4-DIONES FOR TREATING CARDIAC DISEASES | August 2023 | February 2025 | Allow | 19 | 1 | 0 | Yes | No |
| 18228609 | SUBSTITUTED PYRIDO[3,4-b]INDOLE-3-CARBOXYLIC ACIDS AS CK2 INHIBITORS | July 2023 | December 2023 | Allow | 5 | 1 | 1 | Yes | No |
| 18228602 | SUBSTITUTED PYRIDINES AS IRREVERSIBLE INHIBITORS OF MENIN-MLL INTERACTION | July 2023 | June 2024 | Allow | 10 | 0 | 0 | Yes | No |
| 18224515 | PROCESS FOR PREPARING SOLUTIONS COMPRISING BIOPTERIN DERIVATIVES | July 2023 | July 2025 | Allow | 23 | 1 | 1 | Yes | No |
| 18355538 | SUBSTITUTED BENZO[f][1,2,4]TRIAZOLO[4,3-a][1,4]DIAZEPINES AS GABA A GAMMA1 POSITIVE ALLOSTERIC MODULATORS | July 2023 | June 2025 | Abandon | 23 | 1 | 0 | Yes | No |
| 18223002 | SUBSTITUTED PYRIDO[4',3':5,6]PYRIMIDO[1,2-a]INDOLES AS CK2 INHIBITORS | July 2023 | October 2023 | Allow | 3 | 1 | 1 | Yes | No |
| 18221438 | SUBSTITUTED PYRIDO[4',3':5,6]PYRAZINO[1,2-a]INDOLES AS ANTICANCER AGENTS | July 2023 | October 2023 | Allow | 3 | 1 | 1 | Yes | No |
| 18221590 | SUBSTITUTED PYRROLO[2,3-c][2,7]NAPHTHYRIDINES AS CK2 INHIBITORS | July 2023 | November 2023 | Allow | 4 | 1 | 1 | Yes | No |
| 18351264 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | July 2023 | October 2025 | Abandon | 27 | 2 | 0 | No | No |
| 18220196 | SUBSTITUTED PYRAZOLOPYRAZINES, IMIDAZOPYRAZINES AND [1,2,4]TRIAZOLOPYRAZINES AS ALLOSTERIC SHP2 INHIBITORS | July 2023 | March 2025 | Allow | 20 | 1 | 0 | Yes | No |
| 18345840 | SUBSTITUTED BENZODIAZOLIUMS AS ENAC INHIBITORS | June 2023 | March 2025 | Allow | 20 | 1 | 0 | Yes | No |
| 18216566 | SUBSTITUTED PIPERIDINE-2,6-DIONE COMPOUNDS AND METHODS OF USE THEREOF | June 2023 | September 2024 | Abandon | 15 | 2 | 1 | Yes | No |
| 18216441 | COMPOUNDS AND USES THEREOF | June 2023 | May 2024 | Abandon | 10 | 0 | 1 | No | No |
| 18216362 | COMPOUNDS AND USES THEREOF | June 2023 | July 2024 | Abandon | 12 | 0 | 1 | No | No |
| 18339516 | SUBSTITUTED BENZAMIDES AS INTERMEDIATES IN THE SYNTHESIS OF INHIBITORS OF TYROSINE KINASE ENZYMATIC ACTIVITY | June 2023 | October 2024 | Allow | 16 | 1 | 1 | Yes | No |
| 18336124 | ANTI-ONCOGENIC PHYTOCHEMICALS COMPRISING SUBSTITUTED HENICOSANOIC ACID AND HENICOSENOIC ACID | June 2023 | January 2024 | Allow | 7 | 1 | 1 | Yes | No |
| 18335262 | SUBSTITUTED 1,2,4-TRIAZOLES AS TYK2 INHIBITORS | June 2023 | February 2025 | Allow | 20 | 1 | 0 | No | No |
| 18207807 | SUBSTITUTED PYRIDO[2,1-a]ISOQUINOLINES AS VMAT2 INHIBITORS | June 2023 | January 2025 | Allow | 19 | 1 | 0 | No | No |
| 18208023 | SUBSTITUTED ISOINDOLINES AS PI3K-ALPHA INHIBITORS | June 2023 | January 2024 | Allow | 7 | 1 | 0 | No | No |
| 18327607 | PHARMACEUTICAL COMPOSITIONS COMPRISING 4-((6bR,10aS)-3-METHYL-2,3,6b,9,10,10a-HEXAHYDRO-1H,7H-PYRIDO[3',4':4,5]PYRROLO[1,2,3-de]QUINOXALIN-8-YL)-1-(4-FLUOROPHENYL)BUTAN-1-ONE FOR TREATING CENTRAL NERVOUS SYSTEM DISORDERS | June 2023 | November 2024 | Allow | 18 | 1 | 0 | Yes | No |
| 18202694 | TREATMENT OF INFLAMMATORY DISORDERS | May 2023 | July 2025 | Abandon | 26 | 1 | 0 | No | No |
| 18199900 | SUBSTITUTED IMIDAZO[1,2-a]QUINAZOLINES AND IMIDAZO[1,2-a]PYRIDO[4,3-e]PYRIMIDINES AS INHIBITORS OF PARG | May 2023 | November 2023 | Allow | 6 | 1 | 0 | Yes | No |
| 18197979 | PROCESS FOR PREPARING AN AMORPHOUS FORM OF 2-[3-[4-AMINO-3-(2-FLUORO-4-PHENOXYPHENYL)PYRAZOLO[3,4-d]PYRIMIDIN-1-YL]PIPERIDINE-1-CARBONYL]-4-METHYL-4-[4-(OXETAN-3-YL)PIPERAZIN-1-YL]PENT-2-ENENITRILE | May 2023 | June 2025 | Allow | 25 | 2 | 0 | No | No |
| 18314785 | PHARMACEUTICAL COMPOSITIONS COMPRISING 4-((6bR,10aS)-3-METHYL-2,3,6b,9,10,10a-HEXAHYDRO-1H,7H-PYRIDO[3',4':4,5]PYRROLO[1,2,3-de]QUINOXALIN-8-YL)-1-(4-FLUOROPHENYL)BUTAN-1-OL FOR TREATING CENTRAL NERVOUS SYSTEM DISORDERS | May 2023 | October 2024 | Allow | 18 | 1 | 0 | Yes | No |
| 18140370 | SUBSTITUTED PYRIDINES AS PARP1 INHIBITORS | April 2023 | August 2023 | Allow | 3 | 1 | 0 | Yes | No |
| 18140402 | SUBSTITUTED IMIDAZO[l,2-a]PYRAZINES AND PYRAZINO[l,2-a] PYRIMIDINES AS TOPICAL AGENTS FOR DERMATOLOGICAL APPLICATIONS | April 2023 | August 2024 | Allow | 15 | 1 | 1 | Yes | No |
| 18306649 | CRYSTALLINE FORMS OF 2-[3-[4-AMINO-3-(2-FLUORO-4-PHENOXYPHENYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-1-YL]PIPERIDINE-1-CARBONYL]-4,4-DIMETHYLPENT-2-ENENITRILE | April 2023 | December 2024 | Allow | 20 | 1 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner WILLIS, DOUGLAS M.
With a 66.7% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 38.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner WILLIS, DOUGLAS M works in Art Unit 1624 and has examined 2,080 patent applications in our dataset. With an allowance rate of 77.4%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 21 months.
Examiner WILLIS, DOUGLAS M's allowance rate of 77.4% places them in the 44% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by WILLIS, DOUGLAS M receive 1.50 office actions before reaching final disposition. This places the examiner in the 26% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by WILLIS, DOUGLAS M is 21 months. This places the examiner in the 90% percentile for prosecution speed. Applications move through prosecution relatively quickly with this examiner.
Conducting an examiner interview provides a +22.0% benefit to allowance rate for applications examined by WILLIS, DOUGLAS M. This interview benefit is in the 67% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 35.9% of applications are subsequently allowed. This success rate is in the 81% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 67.4% of cases where such amendments are filed. This entry rate is in the 90% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 25.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 29% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 95.6% of appeals filed. This is in the 85% percentile among all examiners. Of these withdrawals, 72.3% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 73.8% are granted (fully or in part). This grant rate is in the 80% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 5.0% of allowed cases (in the 86% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 11.1% of allowed cases (in the 89% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.